Stony Brook University and GlycoMira Therapeutics Receive $1.5M for Developing New Treatment for Periodontal Disease

Posted on October 11, 2013


Stony Brook, NY -  A Small Business Innovation Research (SBIR) award was issued by the National Institute of Dental & Craniofacial Research (NIDCR) to support the continued development of a semi-synthetic glycosaminoglycan ether (SAGE) technology to better manage periodontal disease, which is the most prevalent chronic inflammatory condition known to man without any known cure.

Based on the preclinical results obtained during a previously awarded SBU/GlycoMira Phase I SBIR, GlycoMira's SAGEs were found to block multiple pathways of periodontal disease progression. Additionally, by targeting receptors for advanced glycation end-products or RAGE pathophysiology, SAGE has a high potential to impact the difficult-to-treat subset of periodontal patients comprising of people with diabetes and smokers.

“We have been committed to increasing awareness of the often silent gum disease known as periodontitis which if not treated properly can have a significant impact on overall health. This is particularly important to share with the diabetes community as there are short and long-term implications that untreated periodontitis may have on a successful, comprehensive diabetes management plan,” said Dr. Maria Emanuel Ryan, a co-PI on this grant and the Professor and Chair of Oral Biology & Pathology at Stony Brook University. “We are thrilled to see this innovative technology, that will provide us with new therapeutic options to better manage periodontitis, move to the next phase of preclinical development and we look forward to working with GlycoMira to eventually introduce this new technology into the clinical setting and the practice of dentistry”, said Dr. Ryan. Dr. Ying Gu of the Department of General Dentistry at Stony Brook’s School of Dental Medicine will serve as a co-investigator on this grant.

“We are delighted to have the financial support necessary to continue development of this promising therapeutic innovation for oral biology and pathology,” said GlycoMira’s CSO and co-PI, Dr. Glenn D. Prestwich, also a professor of medicinal chemistry at the University of Utah.  GlycoMira’s SAGE technology consists of a proprietary class of metabolically stabilized polysaccharidesthat are systemically and topically safe anti-inflammatory agents. The pilot studies in the first SBIR grant period demonstrated that GlycoMira’s lead compound, GM-0111, reduced key molecules involved in the destructive processes that lead to bone loss in an accelerated model of periodontal disease. “We are committed to improving the lives of people through focused efforts in translational medicine, and we will stay focused on getting this new technology from the bench to the mouth for everyone to use.”

© 2016 AEGIS Communications | Privacy Policy